The company has mastered the whole industrial chain of preparing human insulin in pathogen-free transgenic pigs and achieving large-scale extraction of the porcine islets. Clinical studies on diabetic patients will be completed in January 2017. The company works also on xenotransplantation of porcine islets, and it is expected that 5 patients will undergo surgery in September at Third Xiangya Hospital, Central South University (Professor WANG Wei). The company estimates that about 4 million diabetes-1 patients among 100 million Chinese diabetics might become potential customers of their product.

China Bio news release, August 26, 2016